Gleevec variation prevents morphine tolerance in chronic pain patients

The incredible breakthrough blockbuster leukemia drug Gleevec has saved tens of thousands of lives over the last decade or so, turning chronic myeloid leukemia into a manageable disease, whereas it used to be a death sentence.

Now, researchers at the Departments of Anesthesiology/Perioperative Medicine and Biochemistry at MD Anderson believe they have found another very useful application of Gleevec-- preventing tolerance in morphine patients.

Despite the development of other narcotic agents, morphine remains the gold standard for pain control and management. Unfortunately over time tolerance develops and the drug becomes ineffective.

According to the study published online in Nature Medicine, researchers have found a cellular signal that selectively causes narcotic tolerance. Using a reformulated version of Gleevec, researchers were able to prevent tolerance from developing in mice models, and even reverse it in morphine-tolerant mice.

Said one researcher, "By suggesting a way to prevent or reverse tolerance in patients, this study could have far-reaching implications for many people suffering with chronic intractable pain," including cancer patients.

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap